MA35090B1 - Polythérapie pour les malignités hématologiques - Google Patents
Polythérapie pour les malignités hématologiquesInfo
- Publication number
- MA35090B1 MA35090B1 MA36292A MA36292A MA35090B1 MA 35090 B1 MA35090 B1 MA 35090B1 MA 36292 A MA36292 A MA 36292A MA 36292 A MA36292 A MA 36292A MA 35090 B1 MA35090 B1 MA 35090B1
- Authority
- MA
- Morocco
- Prior art keywords
- hematological malignancies
- combination therapy
- alkyl
- compound
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyesters Or Polycarbonates (AREA)
- Stored Programmes (AREA)
Abstract
L'invention concerne des procédés qui concerne une nouvelle stratégie thérapeutique pour le traitement de malignités hématologiques et de maladies inflammatoires. En particulier, le procédé comporte l'administration d'un composé de la formule a, dans laquelle r représente h, halo ou alkyle en c1-c6 et r' représente alkyle en c1-c6, ou d'un sel de qualité pharmaceutique de ce composé et éventuellement d'un excipient de qualité pharmaceutique, et d'un ou de plusieurs agents thérapeutiques supplémentaires éventuellement choisis dans le groupe constitué par la bendamustine, le rituximab et l'ofatumumab.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452034P | 2011-03-11 | 2011-03-11 | |
US201161493317P | 2011-06-03 | 2011-06-03 | |
PCT/US2012/028654 WO2012125510A1 (fr) | 2011-03-11 | 2012-03-09 | Polythérapies pour des malignités hématologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35090B1 true MA35090B1 (fr) | 2014-05-02 |
Family
ID=45888489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36292A MA35090B1 (fr) | 2011-03-11 | 2013-10-03 | Polythérapie pour les malignités hématologiques |
Country Status (22)
Country | Link |
---|---|
US (3) | US20130064812A1 (fr) |
EP (2) | EP3187184A1 (fr) |
JP (2) | JP2014510729A (fr) |
KR (1) | KR20140022836A (fr) |
CN (1) | CN103826629A (fr) |
AP (1) | AP2013007158A0 (fr) |
AR (1) | AR085668A1 (fr) |
AU (2) | AU2012229266A1 (fr) |
BR (1) | BR112013022801A2 (fr) |
CA (1) | CA2829096A1 (fr) |
CL (1) | CL2013002552A1 (fr) |
CO (1) | CO6821936A2 (fr) |
CR (1) | CR20130517A (fr) |
EA (1) | EA201391263A1 (fr) |
EC (1) | ECSP13012964A (fr) |
MA (1) | MA35090B1 (fr) |
MX (1) | MX2013010439A (fr) |
PE (1) | PE20140405A1 (fr) |
SG (2) | SG10201601909TA (fr) |
TW (1) | TW201242598A (fr) |
UY (1) | UY33947A (fr) |
WO (1) | WO2012125510A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765687B2 (en) | 2005-10-17 | 2014-07-01 | Sloan Kettering Institute For Cancer Research | WT1 HLA class II-binding peptides and compositions and methods comprising same |
CA2645766A1 (fr) | 2006-04-10 | 2007-10-25 | Sloan Kettering Institute For Cancer Research | Peptides wt1 immunogenes et leurs methodes d'utilisation |
WO2009061345A2 (fr) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Ciblage de cdk4 et cdk6 dans une thérapie contre le cancer |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CA2975473C (fr) | 2008-11-13 | 2021-01-19 | Gilead Calistoga Llc | Therapies pour tumeurs malignes hematologiques |
CN103648499B (zh) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | 用于制备异喹啉酮的方法及异喹啉酮的固体形式 |
EP3520810A3 (fr) | 2012-01-13 | 2019-11-06 | Memorial Sloan-Kettering Cancer Center | Peptides wt1 immunogènes et ses utilisations |
CN104870017B (zh) | 2012-11-08 | 2020-08-14 | 理森制药股份公司 | 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物 |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
US9919037B2 (en) | 2013-01-15 | 2018-03-20 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
ES2694328T3 (es) * | 2013-03-12 | 2018-12-19 | Sumitomo Dainippon Pharma Co., Ltd. | Composición acuosa líquida |
CN103271897A (zh) * | 2013-06-04 | 2013-09-04 | 李春启 | 美司那在制备抗血管生成类药物中的应用 |
ES2535452B1 (es) * | 2013-08-02 | 2016-03-02 | Dalana3 S.L. | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas |
CA2931615A1 (fr) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies pour le traitement de troubles myeloproliferatifs |
WO2015160975A2 (fr) * | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
MA40250A (fr) | 2014-07-04 | 2017-05-10 | Lupin Ltd | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k |
CN105380956B (zh) * | 2015-11-04 | 2017-12-19 | 张陆军 | 一种治疗白血病的含艾德拉尼的药物组合物及应用 |
WO2017223422A1 (fr) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Polythérapies |
WO2019108135A1 (fr) | 2017-11-30 | 2019-06-06 | Singapore Health Services Pte. Ltd. | Système et procédé de classification de patients cancéreux dans des groupes de traitement du cancer appropriés et composés pour le traitement du patient |
TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1755609A1 (fr) * | 2004-05-25 | 2007-02-28 | Icos Corporation | Methodes de traitement et/ou de prevention de la proliferation aberrante des cellules hematopoietiques |
CA2975473C (fr) * | 2008-11-13 | 2021-01-19 | Gilead Calistoga Llc | Therapies pour tumeurs malignes hematologiques |
ES2548253T3 (es) * | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Métodos para el tratamiento de tumores sólidos |
IL300955A (en) * | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
-
2012
- 2012-03-09 KR KR1020137026766A patent/KR20140022836A/ko not_active Application Discontinuation
- 2012-03-09 BR BR112013022801A patent/BR112013022801A2/pt not_active IP Right Cessation
- 2012-03-09 JP JP2013557934A patent/JP2014510729A/ja active Pending
- 2012-03-09 SG SG10201601909TA patent/SG10201601909TA/en unknown
- 2012-03-09 CA CA2829096A patent/CA2829096A1/fr not_active Abandoned
- 2012-03-09 US US13/417,180 patent/US20130064812A1/en not_active Abandoned
- 2012-03-09 SG SG2013067129A patent/SG193337A1/en unknown
- 2012-03-09 AP AP2013007158A patent/AP2013007158A0/xx unknown
- 2012-03-09 AU AU2012229266A patent/AU2012229266A1/en not_active Abandoned
- 2012-03-09 CN CN201280022394.XA patent/CN103826629A/zh active Pending
- 2012-03-09 EP EP17157706.7A patent/EP3187184A1/fr not_active Withdrawn
- 2012-03-09 EA EA201391263A patent/EA201391263A1/ru unknown
- 2012-03-09 PE PE2013002034A patent/PE20140405A1/es not_active Application Discontinuation
- 2012-03-09 WO PCT/US2012/028654 patent/WO2012125510A1/fr active Application Filing
- 2012-03-09 EP EP12710838.9A patent/EP2683377A1/fr not_active Withdrawn
- 2012-03-09 MX MX2013010439A patent/MX2013010439A/es not_active Application Discontinuation
- 2012-03-12 TW TW101108394A patent/TW201242598A/zh unknown
- 2012-03-12 UY UY0001033947A patent/UY33947A/es not_active Application Discontinuation
- 2012-03-12 AR ARP120100805A patent/AR085668A1/es unknown
-
2013
- 2013-09-05 CL CL2013002552A patent/CL2013002552A1/es unknown
- 2013-09-30 CO CO13231986A patent/CO6821936A2/es not_active Application Discontinuation
- 2013-10-03 MA MA36292A patent/MA35090B1/fr unknown
- 2013-10-08 CR CR20130517A patent/CR20130517A/es unknown
- 2013-10-10 EC ECSP13012964 patent/ECSP13012964A/es unknown
-
2015
- 2015-01-16 US US14/599,287 patent/US20150196564A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/199,666 patent/US20170119771A1/en not_active Abandoned
- 2016-07-27 JP JP2016147201A patent/JP2016222700A/ja active Pending
- 2016-09-16 AU AU2016228272A patent/AU2016228272A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2012229266A1 (en) | 2013-05-02 |
AU2016228272A1 (en) | 2016-10-06 |
PE20140405A1 (es) | 2014-03-22 |
WO2012125510A1 (fr) | 2012-09-20 |
BR112013022801A2 (pt) | 2019-09-24 |
CO6821936A2 (es) | 2013-12-31 |
SG10201601909TA (en) | 2016-04-28 |
US20150196564A1 (en) | 2015-07-16 |
UY33947A (es) | 2012-10-31 |
KR20140022836A (ko) | 2014-02-25 |
MX2013010439A (es) | 2014-07-09 |
TW201242598A (en) | 2012-11-01 |
ECSP13012964A (es) | 2014-02-28 |
AP2013007158A0 (en) | 2013-10-31 |
AR085668A1 (es) | 2013-10-16 |
CN103826629A (zh) | 2014-05-28 |
SG193337A1 (en) | 2013-10-30 |
US20130064812A1 (en) | 2013-03-14 |
CR20130517A (es) | 2014-02-12 |
CL2013002552A1 (es) | 2014-09-05 |
CA2829096A1 (fr) | 2012-09-20 |
JP2014510729A (ja) | 2014-05-01 |
EP2683377A1 (fr) | 2014-01-15 |
EP3187184A1 (fr) | 2017-07-05 |
EA201391263A1 (ru) | 2014-06-30 |
US20170119771A1 (en) | 2017-05-04 |
JP2016222700A (ja) | 2016-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35090B1 (fr) | Polythérapie pour les malignités hématologiques | |
EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
UA109698C2 (xx) | Похідні азаіндазолу або діазаіндазолу як медикамент | |
MA34342B1 (fr) | Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer | |
MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
IN2014DN05869A (fr) | ||
MX2020012180A (es) | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. | |
MX2013008056A (es) | 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2). | |
MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
MA35347B1 (fr) | Procedes therapeuiques | |
PH12016501198A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
EA201370230A1 (ru) | Новые ингибиторы rock | |
EP2772481A8 (fr) | Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation | |
UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
RU2013148627A (ru) | Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии | |
MX2014011843A (es) | Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma. | |
RU2013149634A (ru) | Комбинации троспия и стимуляторов слюноотделения для лечения гиперактивного мочевого пузыря | |
WO2022207979A3 (fr) | Nouveaux composés hétérocycliques et leur utilisation | |
MA38599A1 (fr) | Nouveaux dérivés pyrazolopyrrolidine et leur utilisation dans le traitement de maladies | |
JOP20140372B1 (ar) | مشتقات [4،2،1] ثلاثي أزولو[1،5-a] بيريميدين كمثبطات لبروتياسوم الأَوَالِي للاستخدام في علاج الأمراض الطفيلية كداء اللِّيشْمانِيَّاتِ | |
MA35534B1 (fr) | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial |